ScripCipla has received regulatory approval in India for MannKind’s Afrezza setting the stage for the debut of the inhaled insulin in a competitive market that has the second-highest burden of diabetes glo
ScripIdiopathic pulmonary fibrosis (IPF) has proved to be a tough disease to crack, as last year’s trial failures from Galecto Inc. and FibroGen, Inc. have shown. But Boehringer Ingelheim GmbH has de
ScripSweden's Vicore Pharma can now boast Sanofi as a backer as it kicks off mid-stage trials of its idiopathic pulmonary fibrosis (IPF) candidate, buloxibutid. The French drugmaker has committed to s
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Cycle Offers $466m For Vanda, Which Tur